INTRODUCTION
Lung cancer is the most common visceral malignancy, accounting for roughly one-third of all cancer deaths, and it is the most common cause of cancer-related death in both men and women 4. [1] The incidence of lung cancer peaks between age 55 and 65 years. Lung cancer accounts for 29% of all cancer deaths (31% in men and 26% in women). [2] It constitutes 6.8% deaths in India. [3] Lung cancer is major health problem in Kashmir valley and constitutes 9.9% of all cancers. [4] Smoking is the main risk factor for lung cancer, and it also potentiates the effects of many occupational/environmental carcinogenesis. [5] [6] [7] Lung carcinoma is divided into small and non-small cell lung carcinoma (SCLC and NSCLC). Although NSCLC consists of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, it was considered as one group mainly Kasana, et al.: EGFR mutation in adenocarcinoma lung subtype). Other reason is the potential uses of targeted therapy in cases showing epidermal growth factor receptor (EGFR) mutations. [11] NSCLC frequently overexpresses receptors of the ErbB family, including the EGFR. [12, 13] Since the 1980s, many studies showed EGFR overexpression in lung carcinoma particularly in squamous cell carcinoma using various techniques including immunohistochemistry. However, the significance of these over expressions continued to be controversial. The breakthrough took place in 2004 when Lynch et al. [14] reported that activating mutation of EGFR gene kinase domain resulted in responsiveness to tyrosine kinase inhibitors (TKI) in patient with lung adenocarcinoma. Simultaneously two independent group reported similar results. [15, 16] The EGFR (HER-1/ErbB1) is a member of the ErbB family of tyrosine kinase (TK) receptors, which includes HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. It is composed of extracellular (ligand-binding), transmembrane and intracellular (TK) domain. On ligand binding and receptor homo or heterodimerization and activation, activated EGFR signals downstream to the P13K/AKT and RAS/RAF/MAPK pathways. These intracellular signaling pathways regulate key processes such as apoptosis and proliferation. In malignant cells, including NSCLC cells, the activity of the receptor may become dysregulated and no longer under the control of inherent inhibitory mechanism. [17] Spontaneous EGFR mutations often are oncogenic; that is, they activate the EGFR-signaling pathway in the absence of ligand and promote cell proliferation, survival, and anti-apoptotic signals. These signaling networks make EGFR-mutated cells dependent on a functional EGFR for their survival, rendering them addicted to receptor. Inhibition of EGFR leads to up-regulation of pro-apoptotic molecules and finally results in cell death through the activation of the intrinsic mitochondrial apoptotic pathway.
The data regarding the prevalence of EGFR mutation in adenocarcinoma lung from North India is not available. Given the grim prognosis of advanced NSCLC patients and a possible role of targeted therapies in advanced lung cancer, this study was carried out in one of the busiest tertiary care hospitals of North India.
Aims and objectives

To determine the prevalence of EGFR mutation in
Adenocarcinoma Lung in a North Indian population 2. To study the association of EGFR mutation status with different clinical variables such as sex, residence, smoking history, and stage of disease. 
MATERIALS AND METHODS
Sample collection/storage
The tissue specimen resected during surgery or obtained through computed tomography (CT) guided biopsy and bronchoscopy was collected from patients for the study. All tissue specimens were immediately stored at −70°C for nucleic acid extraction. Histopathologically confirmed adenocarcinoma tissues were used for mutational analysis of EGFR genes.
DNA extraction
High molecular weight DNA was isolated from the samples and confirmed by electrophoresis on 1% agarose gel. The concentration of the DNA obtained was measured in a microvolume UV-Vis Spectrophotometer (Thermo Scientific NanoDrop 2000) at 260 nm wavelength. The purity of DNA was checked using A260/A280 ratio.
Epidermal growth factor receptor amplification
Polymerase chain reaction (PCR) amplification using four set of primer pairs that span the mutational cluster region of the EGFR gene were used to amplify exons. The product sizes were 397, 306, 377, and 348 bps . [14, [18] [19] [20] All precautions were taken to ensure contamination free amplification of DNA. Prevention of carry-over by separation of pre-and post-PCR steps, and use of aerosol-free tips were strictly followed. Results were considered valid only on the reproduction of same in two independent experiments.
Molecular analysis [Table 1]
DNA isolated from samples was subjected to PCR for amplification of different exons of EGFR gene. Data Kasana, et al.: EGFR mutation in adenocarcinoma lung from DNA sequencing was analyzed for the alterations in the respective amplicons of EGFR gene. Lung tumor tissue samples were sequenced with the primers used for amplification of the exons of EGFR gene. The sequencing data were analyzed and interpreted manually or using Clustal X software.
DNA sequencing was carried out by automated DNA sequencing method on ABI Prism 310 (Perkin Elmer). The automated DNA sequencing is based on the chain termination reaction. 
C: Lane M, 100 bp ladder; lanes 1-6 amplified product 377 bp (exon 20).
D: Lane M, 100 bp ladder; lanes 1-9 amplified product 348 bp (exon 21).
Statistical methods
The statistical analyses were done by standard statistical methods applicable to the study, including Chi-square/ Student's t-test. Statistical Package for Social Sciences 16.0 (IBM in 2009) and Microsoft Excel Software was used for data analysis. P < 0.05 was taken as significant.
RESULTS
Baseline characteristics
A total of 57 patients were included in the study, all of whom had a diagnosis of Adenocarcinoma lung [ Table 2 ]. Among these 31 (54%) were male and 26 (46%) female. 
Epidermal growth factor receptor mutation and its relation to different clinical variables
A total of 20 (35.1%) patients tested positive for EGFR in this study population [ Table 3 ]. Of these 14 were female and 6 male. EGFR was more frequently detected in female patients (53.8%), while as only 19.4% of the male patients expressed EGFR mutation, which was statistically very significant (P = 0.007) [ Figure 1 ]. There was no significant difference between the expression of EGFR mutation among patients from rural and urban areas (P = 0.43).
There was no significant difference between the expression of EGFR mutation among patients from rural and urban areas (P = 0.43). Seven (35.1%) patients who tested positive for EGFR mutation were smokers while as 13 (64.1%) were nonsmokers [ Figure 2 ]. EGFR mutation was more frequently detected in nonsmokers (52%) as compared to smokers (21.9%), which was also statistically significant with a P value of 0.018. Six (35.1%) patients who tested positive for EGFR mutation had Stage I and II disease while as 14 (64.9%) patients had Stage III and IV disease [ Figure 3 ]. EGFR mutation was more frequent in Stage III and IV adenocarcinomas (48%) as compared to Stage I and II (21.4%) which was statistically significant (P value 0.034).
Type of mutation
EGFR mutation was further qualified with the exon on which deletion had occurred. Exon 19 deletion was seen more frequently (55%) as compared to Exon 21 (30%) and Exon 20 which expressed EGFR mutation (15%) [ Table 4 ].
DISCUSSION
Lung cancer remains one of the most common causes of cancer-related morbidity and mortality worldwide. The A number of mutations have been reported in lung cancer. These mutations, collectively called as oncogenic driver mutations, are responsible for initiation and maintenance of cancer. These mutations are often found in genes that are critical for maintaining normal cellular proliferation and survival, and the presence of such mutations confers a growth advantage on cancer cells. [18] The EGFR is a member of the ErbB family of TK receptors that regulate key processes such as apoptosis and proliferation. In recent years, attention has been paid to the role of driver mutations in EGFR in the tumorigenesis of adenocarcinomas and their potential use as targets for therapy. [14, 18, 20] Different studies report the different prevalence of EGFR mutation in NSCLC, ranging from 43% to 89%. Paez et al. observed EGFR mutation in 32% of adenocarcinoma lung patients while as Kosaka et al. found EGFR mutation in 49% of patient with adenocarcinoma lung. [15, 21] Mitsudomi et al. observed EGFR mutation in 56% of lung tumor whereas Sahoo et al. found EGFR mutation in 51.8% patients of lung cancer. [22, 23] Marchetti et al. found EGFR mutation in 42% of adenocarcinoma patients. In this study, EGFR mutation was found in 35.1% patients. [24] This variation in different studies could be attributed to various factors such as environmental, geographical, and ethnic difference. In addition, this variation can result from technical errors which could occur during storage, transportation, and processing of the sample. It can also result from various methodologies used to detect EGFR mutation in different studies.
Several studies report higher prevalence of EGFR mutations in female lung cancer patients. The reason for this difference is largely unknown. In this study, 53.8% of [25] Tokumo et al. showed the prevalence of EGFR mutation was more in female (67%) compared to male (33%). [26] Tomizawa showed the prevalence of EGFR mutation 16% in female as compared to male 0.075%. [27] Sonobe et al. found that female with adenocarcinoma has a frequency of EGFR mutation of (76.3%) as compared to male (34%). [28] Adenocarcinoma is the most common histologic type of lung cancer in nonsmokers. EGFR mutation follows a similar pattern. Shigematsu et al. observed EGFR mutation in (47%) of nonsmoker patient as compared to (24%) in a patient with smoking history. [29] Kosaka et al. (2004) showed the prevalence of EGFR mutation in (66%) in nonsmoker as compared to (22%) in smoker. [21] The present study also showed that the percentage of EGFR mutation was more in nonsmokers (52%) as compared to smokers (21.9%). Stage of the disease has also been found to be a predictor of EGFR status in certain studies. The prevalence of EGFR mutation has been found to be more in Stage III-IV of lung cancer as compared to Stage I-II. Such an issue, however, remains controversial and whether such findings are just incidental or carry some prognostic significance remains debateable. Although Tomizawa et al. showed a higher prevalence of EGFR mutation in advanced lung cancer; such findings were not seen in studies done by Jang et al. [27, 30] This study, however, supports the claims of former, with EGFR mutation being more common in Stage II-IV disease as compared to Stage I-II disease (48% vs. 21.4% respectively) that was statistically significant. The reasons behind such differences remain to be unknown. However, given the fact that such findings have been found in more than few studies does make it more than incidental.
In this study, we also found that EGFR mutation was most commonly seen in exon-19 (50%) followed by exon-21 (30%) which was followed by exon-20 (15%). This result was in consistent with various studies done previously. Hofman et al. found mutation in exon-19 in 58% cases and exon-21 in 34% of patients. [31] Boch et al. found in their study that exon-19 was mutant in (56%) and exon-21 was mutant in (30%). [32] Unal et al. also found that patients with EGFR mutation on exon-20 are less responsive to TKIs than those with mutation on exon 19 and exon-21. [33] This study revealed the higher percentage of EGFR mutation on exon-20 as compared to other studies. It could because many of our patients were already started on chemotherapy before going for EGFR mutation analysis. Sequist et al. found that expression of Exon-20 mutation is associated with acquired resistance to TKIs and can be due to previous therapy. [34] Furthermore, there may be genetic or racial preponderance which needs further studies for confirmation. Furthermore, it explains the response rate in such patients who are receiving TKIs based chemotherapy. Different studies have found higher prevalence of EGFR mutations in East Asian population as compared to Caucasians (47-64% vs. 10-15%). [35] [36] [37] [38] Only few studies are available from India. Mehta showed 35% of lung cancer patients' harbored EGFR mutation; the majority of whom were Adenocarcinoma with no significant gender difference. [39] Shankar et al. found very high prevalence of EGFR mutation (89%) in adenocarcinoma lung in South Indian population. [40] Pungliya et al. found that South Indians had a higher mutation rate (68% ± 17%) than North Indians (41% ± 21%, P = 0.06). [41] In this study, 35.1% patients of adenocarcinoma lung tested positive for EGFR mutation with statistically significant differences with respect to gender, smoking history, and stage of lung cancer.
CONCLUSION
Lung cancer is a very common malignancy with significant morbidity and mortality. Few treatment options exist for advanced NSCLC. Due to significant treatment-related toxicity patients usually opt out of the treatment protocols which compound the problem. Targeted therapies have come a long way in the management of a variety of diseases including cancers. A number of mutations have been found in lung cancer which has been used as potential therapeutic targets. One such mutation is EGFR mutation which is targeted by TKIs and provides scope for better management of advanced lung cancer patients. The incidence of EGFR mutation has been found higher in Asian population as compared to Western population and hence should be sought in all NSCLCs particularly in non-smoker females with Stage III and IV disease.
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